Dossier assessment
Dapagliflozin (heart failure) - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Dapagliflozin (heart failure) - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Dapagliflozin (heart failure) - Benefit assessment according to §35a Social Code Book V
Dossier assessment
Adults with symptomatic chronic heart failure with reduced ejection fraction
Hint of non-quantifiable added benefit.
Additional information
Federal Joint Committee (G-BA)
2021.05.20 A G-BA decision was published.
Project details
- Project no.
- A20-113
- Commission
- Commission awarded on 30.11.2020 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Heart and circulation
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
The current version 1.1 of the dossier assessment replaces version 1.0 published on 2021-03-01.
Connected Projects
-
Dossier assessment
Dapagliflozin (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Dapagliflozin (type 1 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Dapagliflozin (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V (new scientific findings)
Status: Commission completed
-
Dossier assessment
Dapagliflozin - Benefit assessment according to § 35a Social Code Book V (dossier assessment)
Status: Commission completed
-
Addendum
Dapagliflozin (heart failure) - Addendum to Commission A20-113
Status: Commission completed
-
Dossier assessment
Dapagliflozin (heart failure with preserved ejection fraction) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Dapagliflozin (type 2 diabetes mellitus in children and adolescents) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Dapagliflozin (kidney disease) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed